A significant gender disparity has emerged from a major international cardiac trial examining beta blocker efficacy after uncomplicated heart attacks. Women taking beta blockers demonstrated a 46% higher risk of adverse events—including death, myocardial infarction, and hospitalization—compared to women not receiving the medication (9.5% versus 6.5% at 3.5-year follow-up). This concerning finding contrasts with men, who showed minimal differences between treatment groups (8.5% versus 8.2%). The study of 5,020 patients across multiple international centers represents the largest trial of its kind, providing robust evidence for sex-specific treatment considerations. These results suggest that beta blockers may pose particular risks for female cardiac patients and warrant urgent clinical reassessment, potentially affecting millions of women worldwide receiving this standard post-heart attack therapy.
Was this article helpful?
